SIFI İlaç A.Ş. bunu yeniden yayınladı
🌟 Exciting News! 🌟 I am thrilled to share our collaboration with the University of California, San Francisco (UCSF) to improve the management of Acanthamoeba Keratitis (AK). The Parasitic Ulcer Treatment Trial (PUTT), led by Dr. Jeremy Keenan at UCSF, aims to understand the role of topical corticosteroids after the initiation of anti-amoebic therapy. SIFI is proud to support this trial with our proprietary polihexanide 0.08%, commercially available in Europe under the brand name Akantior®. The first US patient has received our drug on March 6, 2025, and we are excited about the potential impact this study will have on patient outcomes. Our support to UCSF, 9 more US Centers of Excellence in Cornea and beyond, is a testament to our dedication to innovation in ophthalmology. Join me, Jelle Kleijn and Michelle Liu at the World Cornea Congress 2025 in Washington, DC, from March 20-22, 2025. Let's connect and discuss how to improve outcomes for patients affected by this ultra-rare and severe condition! #Ophthalmology #ClinicalTrials #Innovation #Healthcare #SIFI #UCSF #AcanthamoebaKeratitis